Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: cardiovascular disease

What Do Diabetes, Islet Cells & Autoimmunity Have in Common?

Simon M. Helfgott, MD  |  August 15, 2017

“Man may be the captain of his fate, but he is also the victim of his blood sugar.” —Wilfrid Oakley, MB BChir, an early pioneer in diabetes care Perusing the list of the most notable medical achievements in the 20th century, a reader may conclude that the discovery of insulin should rank in a category…

Filed under:ConditionsOpinionRheuminationsSpeak Out Rheum Tagged with:AutoimmuneCharles BestdiabetesdiscoveryDr. Frederick Bantingglucoseinsulinislet cellsPathogenesispatient careTreatment

TNF Stabilizes Inflammatory RNA in Synoviocytes

Lara C. Pullen, PhD  |  August 14, 2017

A recent study has helped researchers gain insight into the genome-wide regulation of mRNA stability in RA fibroblast-like synoviocytes (FLS). Chronic exposure of FLS to tumor necrosis factor appears to increase mRNA stability, enhancing the expression of inflammatory genes and the perpetuation of synovitis…

Filed under:ConditionsRheumatoid Arthritis Tagged with:fibroblast-like synoviocytesRheumatoid Arthritis (RA)RNAtumor necrosis factor inhibitor

What Rheumatologists Are Paid

Richard Quinn  |  July 28, 2017

A 2017 survey showed that rheumatologists’ pay has plateaued. And according to Anne Bass, MD, many cognitive fields, such as pediatrics and endocrinology, remain underpaid due to the current reimbursement structure…

Filed under:Professional Topics Tagged with:CompensationrheumatologistrheumatologysalariesSalary

Rheumatology Drug Updates: Uncertain Future for Romosozumab, Plus FDA Approves Tocilizumab for GCA

Michele B. Kaufman, PharmD, BCGP  |  July 20, 2017

Romosozumab’s Future Is Uncertain Romosozumab, which has the possible U.S. brand name Evenity, is awaiting approval from the FDA.1 The treatment is an investigational, injectable biologic for treating osteoporosis. It increases bone formation and bone density, reducing a patient’s risk of fractures. The manufacturer no longer expects the FDA to approve the drug this year…

Filed under:ConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:amputationApprovalsbonecanagliflozindrugFDAFracturesGiant Cell ArteritisMedicationMyocardial infarctionNSAIDOsteoporosisrheumatologyriskromosozumabSafetytocilizumabTreatment

How to Document a Patient’s Medical History

From the College  |  July 13, 2017

The levels of service within an evaluation and management (E/M) visit are based on the documentation of key components, which include history, physical examination and medical decision making. The history component is comparable to telling a story and should include a beginning and some form of development to adequately describe the patient’s presenting problem. To…

Filed under:Billing/CodingFrom the CollegePractice Support Tagged with:BillingCenters for Medicare & Medicaid Services (CMS)CodingDocumentationguidelineoffice visitpatient carephysicianpractice management. evaluationReimbursementrheumatologistrheumatology

Sanofi to Invest Further in Biologics

Matthias Blamont  |  June 14, 2017

PARIS (Reuters)—Sanofi announced plans to invest 600 million euros ($673 million) annually over the next two to three years in the field of biologics production, an area of strong growth potential. In contrast to most drugs that are chemically synthesized, many biologics are produced using living cells. They are seen as a promising answer in…

Filed under:Biologics/DMARDsDrug Updates Tagged with:BiologicsSanofi

Rheumatologists Concerned High Healthcare Costs May Encourage Patients to Forgo, Delay Treatment

Susan Bernstein  |  June 14, 2017

While members of Congress debate healthcare legislation, rheumatologists say many of their patients struggle to afford everything from generic drugs to insurance copayments for physical therapy. “It’s a mess. The cost of prescriptions and the rationale for those rising costs in the U.S. right now—it’s just a mess,” says James R. O’Dell, MD, Stokes-Shackleford Professor of…

Filed under:Practice Support Tagged with:BiologicsBiosimilarsCompliancecostsdruggenericHealthcareMedicationpatient careRheumatic DiseaserheumatologistTreatment

NSAIDs Increase MI Risk; Plus New Label Warnings for Canagliflozin

Michele B. Kaufman, PharmD, BCGP  |  May 29, 2017

NSAIDs Increase Myocardial Infarction Risk According a recent meta-analysis of real-world non-steroidal anti-inflammatory drug (NSAID) use, NSAIDs may increase the risk of acute myocardial infarction (AMI). The analysis used individual patient data meta-analysis of studies from healthcare databases in Canada, Finland and the U.K. to determine the time course for risk of AMI, as well…

Filed under:AnalgesicsDrug Updates Tagged with:canagliflozindiabetesFDAFood and Drug AdministrationheartMyocardial infarctionNonsteroidal anti-inflammatory drugs (NSAIDs)NSAIDs

Insufficient Evidence Regarding Osteoporosis Medications in Kidney Patients

Will Boggs, MD  |  April 11, 2017

NEW YORK (Reuters Health)—There are insufficient data to make evidence-based decisions regarding the benefits and harms of osteoporosis medications in patients with chronic kidney disease (CKD), according to a systematic review and meta-analysis. “We found low to moderate evidence for the effects of some but not all of the medications, and the evidence was limited…

Filed under:Biologics/DMARDsConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:biophosphonatesbone mineral density (BMD)chronic kidney diseasedenosumabkidneyOsteoporosisosteoporosis treatments

How to Leverage Physical Therapy & Technology to Help Patients Stay Fit & Decrease Pain

Carina Stanton  |  March 28, 2017

For patients living with rheumatic diseases, the benefits of physical therapy and exercise cannot be overstated. “Working with a physical therapist provides a chance for careful evaluation of how the patient is moving and experiencing pain,” says Maura Iversen, BSc, PT, DPT, SD, MPH…

Filed under:Conditions Tagged with:Exercise/physical therapyphysical activityPhysical TherapyTechnology

  • « Previous Page
  • 1
  • …
  • 50
  • 51
  • 52
  • 53
  • 54
  • …
  • 64
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences